Ensign Peak Advisors
KPTI icon

Ensign Peak Advisors’s Karyopharm Therapeutics KPTI Stock Holding History

Ensign Peak Advisors’s Portfolio KPTI Stock Details KPTI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-2,892
Closed -$237K – 2011
2022
Q3 		$237K Hold
2,892
– – ﹤0.01% 1804
2022
Q2 		$196K Hold
2,892
– – ﹤0.01% 1799
2022
Q1 		$320K Hold
2,892
– – ﹤0.01% 1730
2021
Q4 		$279K Buy
+2,892
New +$288K ﹤0.01% 1841

Other funds holding KPTI

APM
Avidity Partners Management Dallas, Texas $936M AUM 195% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Jacobs Levy Equity Management
Jacobs Levy Equity Management Florham Park, New Jersey $23.8B AUM 25.4% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return

Ensign Peak Advisors's KPTI Position: Q4 2022 in Review

Ensign Peak Advisors sold out of Karyopharm Therapeutics (KPTI) in Q4 2022, closing a stake of 2,892 shares — an estimated $237K sold.

Ensign Peak Advisors first reported a position in KPTI in Q4 2021 and held it in 4 quarters. The position peaked at $320K in Q1 2022. 154 funds tracked by Wall St. Rank hold KPTI as of Q4 2022.

  • Ensign Peak Advisors reported no remaining Karyopharm Therapeutics position as of Q4 2022 after selling out during the quarter.
  • Ensign Peak Advisors sold 2,892 Karyopharm Therapeutics shares in Q4 2022, an estimated $237K.
  • Ensign Peak Advisors first reported a position in Karyopharm Therapeutics in Q4 2021 and held it in 4 quarters.
  • Ensign Peak Advisors's Karyopharm Therapeutics position peaked at $320K in Q1 2022.
  • 154 funds tracked by Wall St. Rank held Karyopharm Therapeutics as of Q4 2022.

Based on Ensign Peak Advisors's 13F filing for Q4 2022, filed 13 Feb 2023.